Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 30, 2018
Issued Date -
N/A
app pub date -
Aug 27, 2015
filing date -
Oct 16, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2015 Application Filing Year
- A61K Class
- 16157 Applications Filed
- 11882 Patents Issued To-Date
- 73.55 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 5 Citation Count
- A61K Class
- 50.93 % this patent is cited more than
- 7 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jul 30, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jul 30, 2029 |
